Literature DB >> 15247772

Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment.

Xian-Jun Qu1, Jia-Lin Yang, Pamela J Russell, David Goldstein.   

Abstract

PURPOSE: We examined the regulation of epidermal growth factor (EGF) receptor (EGFR) expression in human bladder cancer cell lines by interferon-alpha (IFN-alpha), the ability of IFN-alpha to inhibit cell proliferation and the sensitivity of IFN-alpha pretreated cells to EGF.
MATERIALS AND METHODS: Cell proliferation was determined using crystal violet colorimetric and clonogenic assays. EGFR expression was measured by flow cytometry using specific antibody or ligand binding approaches.
RESULTS: After IFN-alpha (100 IU/ml) treatment cell surface EGFR expression was upregulated in 6 of 11 and down-regulated in 2 of 11 bladder cancer cell lines. The over expression of cell surface EGFR peaked within 48 to 96 hours and increased by 35% to 241% in individual cell lines. High level cell surface EGFR correlated with intracellular EGFR expression. Cell growth inhibition by IFN-alpha coexisted with EGFR over expression in the 6 lines. IFN-alpha treated cells remained sensitive to EGF treatment.
CONCLUSIONS: IFN-alpha transiently up-regulates EGFR expression and inhibits in vitro growth in some human bladder cancer cells. IFN-alpha does not prevent EGFR from binding EGF or signal transduction via the EGF-EGFR pathway. This may have clinical implications for improving treatment based on EGFR targeting in select patients with bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247772     DOI: 10.1097/01.ju.0000130751.83953.55

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells.

Authors:  Hao Li; Lulu Hui; Wenlin Xu; Huiling Shen; Qiaoyun Chen; Lulu Long; Xiaolan Zhu
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

2.  LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.

Authors:  Jian-Jun Gao; Zu-Hua Gao; Cui-Rong Zhao; Yi Yuan; Shu-Xiang Cui; Xiao-Fan Zhang; Yan-Na Cheng; Wen-Fang Xu; Wei Tang; Xian-Jun Qu
Journal:  Invest New Drugs       Date:  2010-01-29       Impact factor: 3.850

3.  Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.

Authors:  Jian Liu; Wen-Fang Xu; Shu-Xiang Cui; Yong Zhou; Yun-Xia Yuan; Ming-Hui Chen; Ruo-Han Wang; Ruo-Yan Gai; Masatoshi Makuuchi; Wei Tang; Xian-Jun Qu
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

4.  [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Authors:  B A Hadaschik; K Zhang; A I So; J C Bell; J W Thüroff; P S Rennie; M E Gleave
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 5.  Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.

Authors:  Beata Zahorowska; Philip J Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

6.  Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo.

Authors:  Shigeru Sasaki; Tadao Ishida; Minoru Toyota; Akinobu Ota; Hiromu Suzuki; Akinori Takaoka; Hiroshi Yasui; Hiroyuki Yamamoto; Hideyasu Takagi; Masahiro Maeda; Tsutomu Seito; Masayuki Tsujisaki; Yasuhisa Shinomura; Kohzoh Imai
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

7.  Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.

Authors:  Aayush Aayush; Saloni Darji; Deepika Dhawan; Alexander Enstrom; Meaghan M Broman; Muhammad T Idrees; Hristos Kaimakliotis; Timothy Ratliff; Deborah Knapp; David Thompson
Journal:  Oncotarget       Date:  2022-09-06

8.  Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

Authors:  Chi Pan; Shanshan Weng; Yin Duan; Ling Ding; Suzhan Zhang; Jianjin Huang
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.